DFTX
NASDAQ · Pharmaceuticals
Definium Therapeutics Inc
$37.65
-2.67 (-6.62%)
DFTX News3 articles
AtaiBeckley Surges on FDA Psychedelic Guidance, BPL-003 Duration Advantage
AtaiBeckley (ATAI) shares surged 15.6% as FDA staffing guidance for psychedelic trials boosted BPL-003's two-hour clinic model, potentially reducing monitoring costs vs. longer treatments.
Definium Shares Surge on LSD-Based Depression Drug Trial Success
DFTX shares soared 64.2% premarket after Definium's Phase 3 Emerge trial showed DT120 achieved an 8.1-point placebo-adjusted benefit in major depressive disorder.
Definium's Psychedelic Drug DT120 Gains Analyst Backing Ahead of Key 2026 Data
Definium Therapeutics advanced after Stifel and Piper Sandler issued Buy ratings, spotlighting its LSD-based drug DT120 in late-stage trials for anxiety and depression. The company will host an investor day on April 22 to discuss upcoming Phase 3 data expected through 2026.